DERM
Journey Medical Corp

3,059
Mkt Cap
$239.68M
Volume
226,331.00
52W High
$9.30
52W Low
$3.54
PE Ratio
-23.31
DERM Fundamentals
Price
$9.11
Prev Close
$9.19
Open
$9.10
50D MA
$7.50
Beta
0.56
Avg. Volume
164,621.70
EPS (Annual)
-$0.7181
P/B
11.11
Rev/Employee
$1.37M
Loading...
Loading...
News
all
press releases
electroCore, Inc. (ECOR) Reports Q3 Loss, Beats Revenue Estimates
electroCore (ECOR) delivered earnings and revenue surprises of -11.11% and +10.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3d ago
News Placeholder
More News
News Placeholder
OmniAb, Inc. (OABI) Reports Q3 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) delivered earnings and revenue surprises of 0.00% and -62.97%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·4d ago
News Placeholder
New Strong Sell Stocks for September 4th
DERM, HOPE and NXRT have been added to the Zacks Rank #5 (Strong Sell) List on September 4, 2025.
Zacks·2mo ago
News Placeholder
Journey Medical Corporation (DERM) Reports Q2 Loss, Beats Revenue Estimates
Journey Medical (DERM) delivered earnings and revenue surprises of -128.57% and +1.11%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·3mo ago
News Placeholder
3 Biotech Stocks Likely to Outpace Q2 Earnings Estimates
Zevra, Inovio and Journey Medical are set for potential earnings beat this week, backed by strong products and positive ESP scores.
Zacks·3mo ago
News Placeholder
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks·3mo ago
News Placeholder
Journey Medical Corporation (DERM) Reports Q1 Loss, Tops Revenue Estimates
Zacks·6mo ago
News Placeholder
The Joint Corp. (JYNT) Reports Q1 Loss, Tops Revenue Estimates
chainwire·6mo ago
News Placeholder
Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Lags Revenue Estimates
chainwire·6mo ago
News Placeholder
What's Going On With Journey Medical Stock Today?
Journey Medical (NASDAQ:DERM) shares are trading higher Monday after the company announced the U.S. Food and Drug Administration approved its Emrosi drug for the treatment of rosacea. read more...
Benzinga·1y ago

Latest DERM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.